LAB - Standard Biotools Inc

LAB - Standard Biotools Inc

https://www.standardbio.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Standard BioTools ( LAB ) Reports Q2 Loss, Tops Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.10

Standard BioTools (LAB) delivered earnings and revenue surprises of 0.00% and +5.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

GlobeNewswire • 1 month, 3 weeks ago • score: 0.51

SOUTH SAN FRANCISCO, Calif., July 21, 2025 ( GLOBE NEWSWIRE ) -- Standard BioTools Inc. ( NASDAQ: LAB ) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at ...

FedEx Issues Soft Guidance, Joins Torrid Holdings, Allot And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Allot ( NASDAQ:ALLT ) , AST SpaceMobile ( NASDAQ:ASTS )

Benzinga • 2 months, 3 weeks ago • score: -0.32

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday. Shares of FedEx Corporation FDX fell sharply in today's pre-market trading following soft first-quarter guidance.

SomaLogic Acquisition Marks Next Step In Illumina's Advanced Biomarker Push - Illumina ( NASDAQ:ILMN ) , Standard BioTools ( NASDAQ:LAB )

Benzinga • 2 months, 3 weeks ago • score: 0.21

Illumina to pay $350 million in cash and up to $75 million in milestones to acquire SomaLogic. Deal expected to close in H1 2026; profitability anticipated by 2027. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here. On Monday, Illumina, Inc.

Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina

GlobeNewswire • 2 months, 3 weeks ago • score: 0.43

Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments. $350 Million In Upfront Cash ...

Standard BioTools to Host Inaugural "Proteomics Roundtable" Webcast Series

GlobeNewswire • 3 months, 2 weeks ago • score: 0.23

Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical development Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

None

52W High

$2.32

52W Low

$0.92

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.29

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-19.22

EV/Revenue (<3 favorable)

1.67

P/S (TTM) (<3 favorable)

2.88

P/B (<3 favorable)

1.17

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

2.68%

Institutions (25–75% balanced)

72.73%

Shares Outstanding

381,995,000

Float

48,262,400

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

172,271,000

Gross Profit (TTM)

84,540,000

EPS (TTM)

-0.37

Profit Margin (>10% good)

-0.70%

Operating Margin (TTM) (higher better)

-0.29%

ROE (TTM) (>15% strong)

-0.30%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.14

Momentum

Bearish momentum

Value

-0.0003

Previous

-0.0036

Trend

Rising

Signal Cross

No cross

As of

Sep. 05, 2025